ClinicalTrials.gg
RecruitingNCT06512883CLIPSUpdated Oct 28, 2026

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

A Phase 3 interventional study of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis (EGPA) and Hypereosinophilia Syndrome (HES), sponsored by AstraZeneca. Recruiting at 15 sites in 10 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.
Updated Oct 28, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Churg-Strauss Syndrome with a site in United States — 8 open to participants now, 12 under way, 4 of them phase 3. Churg-Strauss Syndrome · United States.

Planned enrollment
10th of 13
14 · median 60
Started
2025
the only one that year
Phase 3
6 of 26
2 open now
Primary completion
2028-02
later than 5 of 11 live
Registered
25th of 26
by date
Lead sponsor
3 of 26
AstraZeneca

Among the 26 studies in Churg-Strauss Syndrome with a site in United States, this one is the 10th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 6 in phase 3, reaches primary completion later than 5 of the 11 other live ones, and was the 25th registered.

Churg-Strauss Syndrome

61 studies on the registry are indexed under Churg-Strauss Syndrome; 17 are open to participants now.

Browse Churg-Strauss Syndrome studies →

Open to participants now

8 of the 26 studies in Churg-Strauss Syndrome with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Churg-Strauss Syndrome studies recruiting now, 11 (79%) set no upper age limit and 3 (21%) stop at 75 or younger; 7 take children under 18; 3 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Churg-Strauss Syndrome with a site in United States, or all of them as a file.
02

Study summary

The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.

Read the detailed description

This study is open-label, multicentre, basket study to evaluate the safety, PK, pharmacodynamic (PD), efficacy, and immunogenicity of repeat dosing of benralizumab subcutaneous (SC) every 4 weeks (Q4W) in male and female children with rare eosinophilic diseases.

Paediatric participants with eosinophilic granulomatosis with polyangiitis (EGPA) will be enrolled in the first cohort.

Paediatric participants with hypereosinophilic syndrome (HES) will be enrolled in the second cohort. Additional cohorts in other eosinophilic diseases may be added in future protocol amendments.

The study consists of 3 periods:

  1. Screening period: 1 to 4 weeks
  2. Open-label treatment period: 52 weeks
  3. Open-label extension period: at least 52 weeks (plus safety follow-up [SFU] weeks after last investigational product [IP] administration)

All eligible participants will receive benralizumab SC Q4W during the 52-week open-label treatment period.

All participants who complete the 52-week open-label treatment period on IP will be offered the opportunity to continue into an extension period. The extension period is intended to allow each participant at least an additional one year of treatment with benralizumab.

03

Conditions studied

  • Eosinophilic Granulomatosis With Polyangiitis (EGPA)
  • Hypereosinophilia Syndrome (HES)

Browse trials for

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Cohorts:

  • Male or female participants must be aged 6 to \< 18 years of age at the time of signing the assent form and their caregiver signing the form.
  • Body weight greater than (>=) 15 kilograms (kg).

EGPA Cohort:

  • Therapy with : The prescribed dose of oral corticosteroids (OCS) (greater than [>] 0.1 milligrams per kilogram per day (mg/kg/day), max dose of 50 milligrams per day (mg/day) must be stable (that is, no adjustment of the dose) for at least 4 weeks prior to baseline (Visit 2).
  • therapy: If receiving immunosuppressive therapy, the dosage must be stable for at least 4 weeks prior to baseline (Visit 2).

HES Cohort:

  • Documented HES diagnosis, defined as history of persistent eosinophilia >1500 cells/µL without secondary cause on 2 examinations ≥1 month apart and evidence of eosinophil-mediated organ involvement.
  • Symptomatic active HES, or history of a prior flare, or considered eligible based on disease severity per investigator judgement.
  • AEC ≥1000 cells/µL at screening (Visit 1).
  • Documented negative testing for Fip1-like 1 gene fused with the -derived growth factor receptor alpha gene (FIP1L1-PDGFR) fusion tyrosine kinase gene translocation.

Exclusion criteria

Exclusion Criteria:

All Cohorts:

  • Any current or history of malignancy.
  • History of anaphylaxis to any biologic therapy or vaccine.
  • Known, pre-existing, endocrine, , metabolic, neurological, renal, gastrointestinal, hepatic, haematological, respiratory, or any other system abnormalities.
  • Previous receipt of benralizumab in an interventional clinical study.

EGPA Cohort:

  • Diagnosed with granulomatosis with polyangiitis (previously known as Wegener'granulomatosis) or microscopic polyangiitis.
  • EGPA relapse: any deterioration in EGPA and/or organ-threatening EGPA that per Investigator judgement renders participants unstable in their EGPA within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2).
  • Life-threatening EGPA: imminently life-threatening EGPA disease within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2), as per Investigator judgement.

HES Cohort:

  • Life-threatening HES or HES complications, as judged by the investigator.
  • Hypereosinophilia of unknown significance (HE-US).
  • Diagnosis of systemic mastocytosis.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (estimated)

Study arms

  • Experimental
    EGPA/HES Cohort: Benralizumab

    Participants with greater than or equal to (\>=) 35 kg weight will receive benralizumab dose-1 and participants with less than (\<) 35 kg weight will receive benralizumab dose-2 as SC injection Q4W during the 52-week treatment period. All participants who complete the 52-week treatment period will be offered the opportunity to continue into an extension period.

    Drug: Benralizumab

Interventions

  • Benralizumab will be administered as SC injection on Q4W.

    Also known as: FASENRA

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    The safety and tolerability of benralizumab will be evaluated.

    Time frame: From screening (Week -4 to -1) until Week 52

  2. Serum Concentrations of Benralizumab

    The PK of benralizumab will be evaluated.

    Time frame: Weeks 0, 12, 24, 25, 36, and 52

Secondary outcomes

  1. EGPA Cohort: Percentage of Participants with Remission at Week 24

    Remission defined as Paediatric Vasculitis Activity Score (PVAS) = 0 and oral corticosteroid (OCS) intake less than or equal to (\<=) 0.1 mg/kg/day.

    Time frame: At Week 24

  2. Number of Participants with Positive Antidrug Antibody (ADA)

    The immunogenicity of benralizumab will be evaluated.

    Time frame: Weeks 0, 12, 24, 36, 48, and 52

  3. Change From Baseline in Peripheral Blood Eosinophil Count

    The PD effect of benralizumab on peripheral blood eosinophil count will be evaluated.

    Time frame: From Baseline to Weeks 0, 12, 24, 36, 52

  4. EGPA Cohort: Time to First EGPA Relapse

    The efficacy of benralizumab on time to first relapse will be assessed. EGPA relapse will be defined as worsening or persistence of active disease since the last visit characterized by: a) Active vasculitis (PVAS \> 0); OR b) Worsening of asthma symptoms (based on Asthma Control Questionnaire - Interviewer Administered \[ACQ-IA\]); OR c) Active nasal and/or sinus disease with worsening in at least one sino-nasal symptom question warranting any of the following: 1) Increase OCS; OR 2) Increase/addition of immunosuppressive medication; OR 3) Hospitalisation related to EGPA worsening.

    Time frame: Up to 52 weeks

  5. HES Cohort: Time to first HES worsening/flare

    The effect of benralizumab on HES worsening/flares will be evaluated.

    Time frame: Up to 52 weeks

  6. HES Cohort: Percentage of participants who experience a HES worsening/flare

    The effect of benralizumab on HES worsening/flares will be evaluated.

    Time frame: Up to 52 weeks

  7. HES Cohort: Number of HES worsening/flares (annualised rate/year)

    The effect of benralizumab on HES worsening/flares will be evaluated. The annualised HES worsening/flare rate will be calculated as follows: The total number of flares \*365.25 / total duration of follow-up in the treatment period (days).

    Time frame: Up to 52 weeks

  8. HES Cohort: Percentage of Participants requiring an increase in corticosteroid dose

    The effect of benralizumab on corticosteroid use will be evaluated.

    Time frame: Up to 52 weeks

  9. HES Cohort: Time to first haematologic relapse

    The time to first haematologic relapse will be defined as the time from first dose of IP to the first post baseline visit with Absolute eosinophil count \[AEC\] ≥ 1000 cells/uL.

    Time frame: Up to 52 weeks

  10. HES Cohort: Percentage of Participants with haematologic relapse

    The effect of benralizumab on haematologic measures of disease activity will be evaluated.

    Time frame: Up to 52 weeks

  11. HES Cohort: Percentage of Participants who have AEC < 500 cells/μL for 24 weeks

    The effect of benralizumab on haematologic measures of disease activity will be evaluated.

    Time frame: Up to 52 weeks

  12. HES Cohort: Patient Global Impression of Change (PGI-C) Score

    The effect of benralizumab on participant/caregiver reported measures of disease severity and health status will be assessed. The PGI-C instrument captures the participant's overall evaluation of response to treatment, and rated on a 7-point PGI-C scale ranging from 1 ('much better') to 7 ('much worse').

    Time frame: Weeks 12, 24, 36 and 48

07

Study locations

13 of 15 sites recruiting
  • Research Site
    Aurora, Colorado 80045, United States
    Recruiting
  • Research Site
    Cincinnati, Ohio 45229, United States
    Recruiting
  • Research Site
    Highland Hills, Ohio 44106-2624, United States
    Recruiting
  • Research Site
    São Paulo, 01232-010, Brazil
    Recruiting
  • Research Site
    Toronto, Ontario M5G1X8, Canada
    Recruiting
  • Research Site
    Lille, 59037, France
    Recruiting
  • Research Site
    Montpellier, 34295, France
    Suspended

    Not enrolling at this site.

  • Research Site
    Ahmedabad, 380052, India
    Recruiting
  • Research Site
    Petah Tikva, 49202, Israel
    Recruiting
  • Research Site
    Guadalajara, 44620, Mexico
    Recruiting
  • Research Site
    Rotterdam, 3015 GD, Netherlands
    Recruiting
  • Research Site
    Kielce, 25-734, Poland
    Recruiting
  • Research Site
    Warsaw, 04-730, Poland
    Not yet recruiting
  • Research Site
    Altındağ, 06230, Turkey (Türkiye)
    Recruiting
  • Research Site
    Istanbul, 34093, Turkey (Türkiye)
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via there quest portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2025 (actual). Primary completion is estimated for Feb 2028, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2024
First posted
Jul 22, 2024
StartActual
Apr 17, 2025
Primary completionEst.
Feb 20, 2028
CompletionEst.
May 14, 2029
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites changed recruiting status (4 now recruiting, 1 now suspended)
Show 5 sites
  • Research Site · Cincinnati, United StatesNot yet recruiting→Recruiting
  • Research Site · Lille, FranceNot yet recruiting→Recruiting
  • Research Site · Montpellier, FranceNot yet recruiting→Suspended
  • Research Site · Ahmedabad, IndiaNot yet recruiting→Recruiting
  • Research Site · Kielce, PolandNot yet recruiting→Recruiting
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    5 sites changed recruiting status (4 now recruiting, 1 now suspended)
    Show 5 sites
    • Research Site · Cincinnati, United StatesNot yet recruiting→Recruiting
    • Research Site · Lille, FranceNot yet recruiting→Recruiting
    • Research Site · Montpellier, FranceNot yet recruiting→Suspended
    • Research Site · Ahmedabad, IndiaNot yet recruiting→Recruiting
    • Research Site · Kielce, PolandNot yet recruiting→Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06512883
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
Apr 17, 2025
Primary completion
Feb 20, 2028 (estimated)
Completion
May 14, 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion